Press Releases Items Per Page 102550 News Category FinancialGeneral Year None202320222021202020192018201720162015201420132012201120102009200820072006 Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Cancer Specialist During 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting Nov 09, 2021 Nektar Therapeutics Reports Third Quarter 2021 Financial Results Nov 04, 2021 Nektar to Announce Financial Results for the Third Quarter 2021 on Thursday, November 4, 2021, After Close of U.S.-Based Financial Markets Oct 26, 2021 Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley Study Sep 21, 2021 Nektar Therapeutics Reports Second Quarter 2021 Financial Results Aug 05, 2021 Nektar to Announce Financial Results for the Second Quarter 2021 on Thursday, August 5, 2021, After Close of U.S.-Based Financial Markets Jul 27, 2021 Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer Jul 19, 2021 Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference Jun 07, 2021 Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity May 20, 2021 Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC) May 18, 2021 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »